Skip to main content

IDEAYA Biosciences, Inc 10-Q for FY2026 Q3

IDEAYA Biosciences, Inc. (IDYA)

10-Q 2026-11-03 For: 2026-09-30
View Original
Added on November 03, 2026

About this 10-Q

IDEAYA Biosciences, Inc filed this 10-Q on November 3, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

IDEAYA Biosciences submitted an NDA to the FDA for the darovasertib combination in metastatic uveal melanoma, stopped enrollment in OptimUM-010, and reported approximately $1.15 billion in cash, cash equivalents and marketable securities as of September 30, 2026. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$10.24M
down 95.1% from $207.83M a year earlier
Net loss
$125.75M
compared with net income of $119.24M a year earlier
Diluted EPS
-$1.22
compared with $1.33 a year earlier